Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Lisdexamfetamine dimesylate

Nature Reviews Drug Discovery volume 6, pages 343–344 (2007)Cite this article

Abstract

Lisdexamfetamine dimesylate (Vyvanse; New River Pharmaceuticals/Shire), a prodrug of D-amphetamine, was approved by the US FDA in February 2007 for the treatment of attention-deficit/hyperactivity disorder.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Elia, J. et al. Treatment of attention-deficit–hyperactivity disorder. N. Engl. J. Med. 340, 780–788 (1999).

    Article  CAS  Google Scholar 

  2. Wilens, T. E. et al. Attention deficit/hyperactivity disorder across the lifespan. Ann. Rev. Med. 53, 113–131 (2002).

    Article  CAS  Google Scholar 

  3. Kratochvil, C. J. et al. Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Pharmacother. 4, 1165–1174 (2003).

    Article  CAS  Google Scholar 

  4. Solanto, M. V. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. 130, 65–71 (2002)

    Article  CAS  Google Scholar 

  5. Biederman, J. & Spencer, T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol. Psychiatry 46, 1234–1242 (1999).

    Article  CAS  Google Scholar 

  6. Wilens, T. E. Mechanism of action of agents used in attention-deficit/hyperactivity disorder. J. Clin. Psychiatry 67 (Suppl. 8), 32–38 (2006).

    CAS  PubMed  Google Scholar 

  7. Food and Drug Administration. FDA labelling information [online], (2007).

  8. Musser, C. J. et al. Stimulant use and the potential for abuse in Wisconsin as reported by school administrators and longitudinally followed children. J. Dev. Behav. Pediatr. 19, 187–192 (1998).

    Article  CAS  Google Scholar 

  9. Poulin, C. Medical and nonmedical stimulant use among adolescents: from sanctioned to unsanctioned use. CMAJ 165, 1039–1044 (2001).

    CAS  PubMed  PubMed Central  Google Scholar 

  10. White, B. P. et al. Stimulant medication use, misuse, and abuse in an undergraduate and graduate student sample. J. Am. Coll. Health 54, 261–268 (2006).

    Article  Google Scholar 

  11. Teter, C. J. et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 26, 1501–1510 (2006).

    Article  Google Scholar 

  12. Babcock, Q. & Byrne, T. Student perceptions of methylphenidate abuse at a public liberal arts college. J. Am. Coll. Health 49, 143–145 (2000).

    Article  CAS  Google Scholar 

  13. Ciccone, P. E. Attempted abuse of Concerta. J. Am. Acad. Child Adolesc. Psychiatry 41,756 (2002).

  14. Stefanatos, G. A. & Baron, I. S. Attention-deficit/hyperactivity disorder: a neuropsychological perspective towards DSM-V. Neuropsychol. Rev. 17, 5–38 (2007).

    Article  Google Scholar 

  15. Fischer, M. & Barkley, R. A. Childhood stimulant treatment and risk for later substance abuse. J. Clin. Psychiatry 64, S11 19–23 (2003).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Josephine Elia is at the Department of Child and Adolescent Psychiatry, The Children's Hospital of Philadelphia, Philadelphia 19104, USA. elia@email.chop.edu,

    Josephine Elia

  2. Chris Easley is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK. ceasley@uk.imshealth.com,

    Chris Easley

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery. p.kirkpatrick@nature.com,

    Peter Kirkpatrick

Authors
  1. Josephine Elia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chris Easley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elia, J., Easley, C. & Kirkpatrick, P. Lisdexamfetamine dimesylate. Nat Rev Drug Discov 6, 343–344 (2007). https://doi.org/10.1038/nrd2315

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2315

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing